Colon CancerNCT06802991
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
A study testing ERAS 3.0 (Enhanced Recovery After Surgery) in people with Colon Cancer and Frailty, run by Copenhagen University Hospital at Herlev at 2 sites in Denmark.
Trial summary
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Colon Cancer, Frailty
- What is being tested?
- ERAS 3.0 (Enhanced Recovery After Surgery)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 2 sitesDenmark
- Study dates
- 1 Apr 2025to 20 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Clinical Frailty Scale preoperative score 4-7 or G8 score ≤ 14
- Nutritional Risk Screening tool (NRS 2002) > 3
- Elective colonic or rectal resection
- Minimally invasive surgical approach (laparoscopic or robotic)
- Patients discharged to own home
- Informed consent to participate
Who cannot join
- Conversion to laparotomy
- Major complications following surgery (Clavien-Dindo >3a)
- Participation in other randomised trials in conflict with the protocol and end- points of the ERAS 3.0 project
- Discharged with tube feeding and parenteral nutrition (partially or completely)
- Known food allergies to dairy or any other ingredient contained in the nutrition package
- Incapable of providing informed consent
- Discharge to 24-hour municipal rehabilitation facility
- All conditions including psychological, geographical, and social factors that could hinder adherence to the trial protocol
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Jacob Rosenberg, Professor, dr.med. contact
Denmark2 sites, 2 recruiting
- Not yet recruiting
University Hospital Herlev
Herlev, 2730
Elna A. Dalsgaard, ph.d.-student, +45 42402296, elna.adalsteinsdottir.dalsgaard@regionh.dk
- Recruiting
University Hospital Herlev
Herlev, 2730
Elna Dalsgaard, +45 42402296, elna.adalsteinsdottir.dalsgaard@regionh.dk
About this study
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.
The study is a randomised controlled trial with two groups: an intervention group receiving the ERAS 3.0 program and a control group recieving standard care. The ERAS 3.0 program includes a comprehensive geriatric health assessment, dietary counseling from a dietitian, and instructions on training and physical activity. These activities will take place in the participant's homes after hospital discharge. Data will be collected at multiple time points: at the hospital, 12 days post-discharge (at the outpatient clinic), and at 1 and 3 months post discharge in the participants' homes.
- Conditions
- Colon Cancer, Frailty
- Being tested
- ERAS 3.0 (Enhanced Recovery After Surgery)
- Keywords
- ERAS 3.0, colon cancer surgery, comprehensive geriatric assessment
- Medical subject headings
- Colonic Neoplasms, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ERAS 3.0 (Enhanced Recovery After Surgery)Other
Nutritional support at discharge and home visits which include comprehensive geriatric assessment, nutritional guidance by dietitian, and instructions on exercise and physical activity.
| Study group | Role | What they receive |
|---|---|---|
| ERAS 3.0 group | Experimental | Post-surgery support at discharge and at home Receives: Other: ERAS 3.0 (Enhanced Recovery After Surgery) |
| Standard care group | No intervention | Standard care, which is no support after discharge |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative recovery
Postoperative recovery is measured as a change in the Quality of Recovery-15 questionnaire. Through 15 questions, the time spent in common postoperative conditions during the last 24 hours is estimated. Each question has a scale from 0 to 10, resulting in a maximum total score of 150.
Measured: 10-14 days after surgery
Secondary outcomes (15)
Health realted Quality of Life (HrQoL)
HrQoL will be measured using the EQ-5D-5L questionnaire. The EQ-5D-5L questionnaire comprises five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five response categories, ranging from having no problems to being unable to perform the activity. The responses are converted into a utility index value, reflecting health status compared to the reference of the general population (norm data). A visual analogue scale (VAS) is also included, where health is rated on a scale from 0 (worst health you can imagine) to 100 (best health you can imagine). Permission will be sought to use the tool.
Measured: 12, 30 and 90 days after surgery
Postoperative recovery
Postoperative recovery is measured as a change in the Quality of Recovery-15 questionnaire. Through 15 questions, the time spent in common postoperative conditions during the last 24 hours is estimated. Each question has a scale from 0 to 10, resulting in a maximum total score of 150.
Measured: 30 and 90 days after surgery
Activities of daily living
Activities in daily living are assessed using the Functional Recovery Score (FRS) to evaluate functional recovery after surgery. The eleven-item questionnaire comprises three main components: basic activities of daily living (BADL), assessed by four items; instrumental activities of daily living (IADL), assessed by six items; and mobility, assessed by one item. BADL accounts for 44 percent of the score, IADL for 23 percent, and mobility for 33 percent. Complete independence results in a score of 100 percent.
Measured: 12, 30 and 90 days after surgery
Energy- and protein intake
Energy and protein intake will be estimated using the 24-hour dietary recall interview method. The interviews will be conducted by the investigator working on the study. The foods and drinks will be entered into the software program Vitakost to calculate the intake of protein (g) and energy (kJ) and liquid (mL). The participant's body weight will be used to calculate the intake per kilogram of body weight. The cut-off for suspecting underreporting will be evaluated retrospectively on an individual basis, taking into account any illness, readmissions, loss of body weight, activity level etc.
Measured: 12, 30 and 90 days after surgery
Appetite
Appetite will be assessed using the Simplified Nutritional Appetite Questionnaire (SNAQ), which consists of four questions adressing appetite, taste, satiety, and meal frequency. Each question offers five possible answers, and participants select the category that best reflects their current situation. The total score ranges from 5 to 20.
Measured: 12, 30 and 90 days after surgery
Weight
Measured: 12, 30 and 90 days after surgery
Physical function and muscle strenght
Physical function and muscle strength will be assessed using the 30-second chair stand test (30s CST), which measures the number of times an individual can rise from and sit down in a standardized chair within 30 seconds. To accommodate participants' abilities, the chair stand test will be modified according to three versions as needed.
Measured: 12, 30 and 90 days after surgery
Muscle mass by BIA
Total and appendicular muscle mass (kg and percent) will be measured by bioelectrical impedance analysis (BIA). This method involves passing a low-level electrical current through the body to measure electrical impedance, or resistance, encountered by the current as it flows through different tissues. Tissues rich in electrolyte-containing water, such as skeletal muscle, have lower resistance and thus higher conductivity. Conductivity is directly proportional to total body water. Lean muscle mass is derived from the conductivity measurement, and fat mass (in kilograms and percentage) is subsequently calculated by subtracting lean muscle mass from total body weight.
Body weight and height are entered manually to aid in calculations.
Measured: 12, 30 and 90 days after surgery as well as 1 (CT) and 3 (CT) years after surgery
Rate of readmission
Readmission rate is defined as any unplanned hospitalisation within 30 days after discharge from hospital.
Measured: within 30 days after discharge
Postoperative complications
The occurrence of post-operative complications, including infections requiring treatment within 30 and 90 days will be registered numerically.
Measured: within 30 and 90 days after discharge
Number of reoperations
The occurence of reoperations will be registered
Measured: within 1 and 6 months after discharge
Total length of hospital stay
Measured: within 6 months after discharge
Days alive and out of the hospital
Measured: within 30 and 90 days after discharge
Mortality
Measured: Within 1, 3, 6, and 12 months after primary surgery
Muscle mass by CT
Muscle mass by will be measured by computed tomography (CT) scan. All CT scans are part of routine care concerning the cancer disease and are therefore not research-related add-ons to routine care.
Measured: at baseline, after one and three years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2025
- Study start1 Apr 2025
- Primary completion30 Apr 2027 (estimated)
- Study completion20 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Colon CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital at Herlev
- Sponsor type
- University, hospital or other
- Collaborators
- Danish Cancer Society
- Responsible party
- Principal investigator, Elna A. Dalsgaard, Copenhagen University Hospital at Herlev
- Investigators
- Jacob Rosenberg, Professor, dr. med., Study director, Center of Perioperative Optimisation, Copenhagen University Hospital at Herlev
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06802991
- Sponsor's protocol ID
- H-24078496
- Status last verified
- Oct 2026
- First submitted
- 19 Jan 2025
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Munk T, Svendsen JA, Knudsen AW, Ostergaard TB, Thomsen T, Olesen SS, Rasmussen HH, Beck AM. A multimodal nutritional intervention after discharge improves quality of life and physical function in older patients - a randomized controlled trial. Clin Nutr. 2021 Nov;40(11):5500-5510. doi: 10.1016/j.clnu.2021.09.029. Epub 2021 Sep 24.
PubMed 34656032Dolin TG, Mikkelsen M, Jakobsen HL, Nordentoft T, Pedersen TS, Vinther A, Zerahn B, Vistisen KK, Suetta C, Nielsen D, Johansen JS, Lund CM. Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial). BMC Geriatr. 2021 Jan 30;21(1):88. doi: 10.1186/s12877-021-02045-9.
PubMed 33516195
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
- ClinicalTrials.gov ID
- NCT06802991
- Acronym / sponsor ID
- H-24078496
- Conditions
- Colon Cancer, Frailty
- Keywords
- ERAS 3.0, colon cancer surgery, comprehensive geriatric assessment
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital at HerlevUniversity, hospital or other
- Collaborators
- Danish Cancer Society
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 20 Dec 2029 (estimated)
- First posted
- 31 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer.
The study is a randomised controlled trial with two groups: an intervention group receiving the ERAS 3.0 program and a control group recieving standard care. The ERAS 3.0 program includes a comprehensive geriatric health assessment, dietary counseling from a dietitian, and instructions on training and physical activity. These activities will take place in the participant's homes after hospital discharge. Data will be collected at multiple time points: at the hospital, 12 days post-discharge (at the outpatient clinic), and at 1 and 3 months post discharge in the participants' homes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ERAS 3.0 group | Experimental | Other: ERAS 3.0 (Enhanced Recovery After Surgery)Post-surgery support at discharge and at home |
| Standard care group | No intervention | –Standard care, which is no support after discharge |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Clinical Frailty Scale preoperative score 4-7 or G8 score ≤ 14
- Nutritional Risk Screening tool (NRS 2002) > 3
- Elective colonic or rectal resection
- Minimally invasive surgical approach (laparoscopic or robotic)
- Patients discharged to own home
Key exclusion criteria (8 listed)
- Conversion to laparotomy
- Major complications following surgery (Clavien-Dindo >3a)
- Participation in other randomised trials in conflict with the protocol and end- points of the ERAS 3.0 project
- Discharged with tube feeding and parenteral nutrition (partially or completely)
- Known food allergies to dairy or any other ingredient contained in the nutrition package
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ERAS 3.0 (Enhanced Recovery After Surgery)Nutritional support at discharge and home visits which include comprehensive geriatric assessment, nutritional guidance by dietitian, and instructions on exercise and physical activity. | Other | ERAS 3.0 group |
Primary outcome
Postoperative recovery
Time frame: 10-14 days after surgery
Postoperative recovery is measured as a change in the Quality of Recovery-15 questionnaire. Through 15 questions, the time spent in common postoperative conditions during the last 24 hours is estimated. Each question has a scale from 0 to 10, resulting in a maximum total score of 150.
15 secondary outcomes
Health realted Quality of Life (HrQoL)
Time frame: 12, 30 and 90 days after surgery
Postoperative recovery
Time frame: 30 and 90 days after surgery
Activities of daily living
Time frame: 12, 30 and 90 days after surgery
Energy- and protein intake
Time frame: 12, 30 and 90 days after surgery
Appetite
Time frame: 12, 30 and 90 days after surgery
Weight
Time frame: 12, 30 and 90 days after surgery
Physical function and muscle strenght
Time frame: 12, 30 and 90 days after surgery
Muscle mass by BIA
Time frame: 12, 30 and 90 days after surgery as well as 1 (CT) and 3 (CT) years after surgery
Rate of readmission
Time frame: within 30 days after discharge
Postoperative complications
Time frame: within 30 and 90 days after discharge
Number of reoperations
Time frame: within 1 and 6 months after discharge
Total length of hospital stay
Time frame: within 6 months after discharge
Days alive and out of the hospital
Time frame: within 30 and 90 days after discharge
Mortality
Time frame: Within 1, 3, 6, and 12 months after primary surgery
Muscle mass by CT
Time frame: at baseline, after one and three years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Background: PubMed 34656032Munk T, Svendsen JA, Knudsen AW, Ostergaard TB, Thomsen T, Olesen SS, Rasmussen HH, Beck AM. A multimodal nutritional intervention after discharge improves quality of life and physical function in older patients - a randomized controlled trial. Clin Nutr. 2021 Nov;40(11):5500-5510. doi: 10.1016/j.clnu.2021.09.029. Epub 2021 Sep 24.
- Background: PubMed 33516195Dolin TG, Mikkelsen M, Jakobsen HL, Nordentoft T, Pedersen TS, Vinther A, Zerahn B, Vistisen KK, Suetta C, Nielsen D, Johansen JS, Lund CM. Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial). BMC Geriatr. 2021 Jan 30;21(1):88. doi: 10.1186/s12877-021-02045-9.
- Individual participant dataSharing planned: No
Related trials for Colon Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
RecruitingPhase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms, Colorectal Neoplasms
RecruitingPhase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
RecruitingObservational study
Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
Peritoneal (Metastatic) Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jacob Rosenberg, Professor, dr.med. contact
Jacob Rosenberg, Professor, dr. med. study director
Center of Perioperative Optimisation, Copenhagen University Hospital at Herlev
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ERAS 3.0 (Enhanced Recovery After Surgery) in people with Colon Cancer and Frailty, run by Copenhagen University Hospital at Herlev at 2 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elna A. Dalsgaard, ph.d. student (+45 42402296, elna.adalsteinsdottir.dalsgaard@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative recovery (time frame: 10-14 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06802991, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.